Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cyclacel Limited, a wholly-owned subsidiary of Cyclacel Pharmaceuticals, has agreed to make changes in its licensing deal with Daiichi Sankyo relating to certain rights of sapacitabine (CYC682), a cell cycle modulating nucleoside analog.
Subscribe to our email newsletter
Sapacitabine is in Phase 3 development for the treatment of acute myeloid leukemia in the elderly and Phase 2 studies for myelodysplastic syndromes and lung cancer.
According to the original agreement signed in September 2003, Daiichi had licensed sapacitabine rights to Cyclacel.
The original agreement allowed Cyclacel to sell sapacitabine following the regulatory approval in at least one country.
Pursuant to the amended agreement, Cyclacel is free of all liabilities and claims.
The royalties which Cyclacel is responsible to pay Daiichi on future net sales of the drug is now increased by 1.25% and 1.50%.